251 related articles for article (PubMed ID: 15455358)
1. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
3. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results of [131I]metaiodobenzylguanidine treatment in metastatic carcinoid tumors.
Colombo L; Vignati A; Lomuscio G; Dottorini ME
J Nucl Biol Med (1991); 1991; 35(4):352-4. PubMed ID: 1823856
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
Prvulovich EM; Stein RC; Bomanji JB; Ledermann JA; Taylor I; Ell PJ
J Nucl Med; 1998 Oct; 39(10):1743-5. PubMed ID: 9776280
[TBL] [Abstract][Full Text] [Related]
6. Role of [131I]metaiodobenzylguanidine therapy in carcinoids.
Hoefnagel CA; Taal BG; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):346-8. PubMed ID: 1726678
[TBL] [Abstract][Full Text] [Related]
7. Results of [131I]metaiodobenzylguanidine treatment in metastatic carcinoid.
Bestagno M; Pizzocaro C; Pagliaini R; Rossini PL; Guerra P
J Nucl Biol Med (1991); 1991; 35(4):343-5. PubMed ID: 1823854
[TBL] [Abstract][Full Text] [Related]
8. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
10. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
[TBL] [Abstract][Full Text] [Related]
11. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
12. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
13. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.
Khan MU; Morse M; Coleman RE
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):441-54. PubMed ID: 19088697
[TBL] [Abstract][Full Text] [Related]
14. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH
J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251
[TBL] [Abstract][Full Text] [Related]
15. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
16. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
17. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.
Shapiro B; Sisson JC; Wieland DM; Mangner TJ; Zempel SM; Mudgett E; Gross MD; Carey JE; Zasadny KR; Beierwaltes WH
J Nucl Biol Med (1991); 1991; 35(4):269-76. PubMed ID: 1823834
[TBL] [Abstract][Full Text] [Related]
18. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma.
Hoefnagel CA; Delprat CC; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):334-6. PubMed ID: 1823851
[TBL] [Abstract][Full Text] [Related]
19. [131I]metaiodobenzylguanidine therapy in carcinoid tumors.
Castellani MR; Di Bartolomeo M; Maffioli L; Zilembo N; Gasparini M; Buraggi GL
J Nucl Biol Med (1991); 1991; 35(4):349-51. PubMed ID: 1823855
[TBL] [Abstract][Full Text] [Related]
20. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
